Citi: Initiates 90-day catalyst observation period for INNOVENT BIO (01801) with a target price of HK$62.
Citibank expects that with the drive of new products, Sinda Bio's strong growth momentum will continue.
Citibank released a research report stating that they have started a 90-day catalyst observation period for INNOVENT BIO (01801). The bank expects that with the drive of new products, the strong growth momentum of INNOVENT BIO will continue. Taletrectinib (ROS1)/Mazdutide/IBI311 (IGF-1R)/IBI112 (IL-23 p19) are expected to be approved in the second half of this year or next year. The target price is 62 Hong Kong dollars, with a rating of "buy/high risk".
Related Articles
CROCODILE(00122): Li Bao'an appointed as alternate director
.png)
HANG YICK HLDGS (01894) appoints Wong Sun Man as an independent non-executive director.
Jiangsu Pacific Precision Forging (300258.SZ) plans to increase capital by 250 million yuan in a Thai company to expand the production capacity of new energy automobiles and engineering machinery gear shafts.
CROCODILE(00122): Li Bao'an appointed as alternate director
HANG YICK HLDGS (01894) appoints Wong Sun Man as an independent non-executive director.
Jiangsu Pacific Precision Forging (300258.SZ) plans to increase capital by 250 million yuan in a Thai company to expand the production capacity of new energy automobiles and engineering machinery gear shafts.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
